News from merrimack pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 30, 2013, 06:00 ET

Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers

 Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced results of a global, Phase 2, open-label, randomized study of MM-121 in...

Jun 04, 2013, 09:00 ET

Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be...

Apr 10, 2013, 09:00 ET

Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model

 Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel bispecific therapy MM-111...

Apr 08, 2013, 08:00 ET

Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel therapy MM-121 restores tumor...

Apr 04, 2013, 08:00 ET

Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet...

Apr 02, 2013, 09:00 ET

Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research data on five novel experimental cancer therapies (MM-398, MM-121,...

Dec 10, 2012, 09:04 ET

Merrimack Pharmaceuticals Presents Promising Phase I Clinical Data for Novel Agent to Treat HER2-positive Breast Cancer and Preclinical Data on Companion Diagnostic

 Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced Phase I clinical trial results for MM-302, the company's novel agent for the...

Nov 27, 2012, 09:00 ET

Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer

Research presented at 2012 SABCS examines cardiac safety profile of MM-302, a new HER2-targeted Liposomal Doxorubicin Agent. Merrimack...

Oct 02, 2012, 08:30 ET

Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers

 Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the presentation of Phase 1 safety and clinical results evaluating two...

Sep 18, 2012, 11:51 ET

Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research evaluating two novel compounds for advanced cancers, including breast,...

Mar 28, 2012, 23:28 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

 Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines...

Jan 12, 2012, 16:31 ET

Phase 1 Data on MM-398 will be Presented at the ASCO 2012 Gastrointestinal Cancers Symposium

 Merrimack Pharmaceuticals, Inc. announced today that Phase 1 results on MM-398, one of its five targeted therapeutic oncology...

Jan 11, 2012, 16:31 ET

Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors

 Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal...

Dec 13, 2011, 16:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers

 Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a...

Nov 30, 2011, 16:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a fully...

Nov 18, 2011, 16:19 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer

   Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of...

Nov 11, 2011, 15:28 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Multiple Programs from Merrimack Pharmaceuticals' Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merrimack Pharmaceuticals, Inc. announced today that they will present seven posters on six novel pipeline programs at the 2011 American...

Oct 11, 2011, 08:46 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully...

Aug 01, 2011, 16:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for the...

Jun 30, 2011, 12:12 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer

Merrimack Pharmaceuticals, Inc. announced today that it will present preclinical data on MM-151, an oligoclonal therapeutic consisting of a...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge